Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Roger B Swartz manages a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This active matter represents the focus of the efforts to protect the associated pharmaceutical research. The volume of pending actions suggests a specific prosecution phase for this portfolio.
The prosecution is handled by 1 distinct examiner and 1 distinct art unit. This indicates that the intellectual property is being reviewed in the assigned administrative environment. For practitioners, this means that the prosecution outcome is dependent on the views of the examiner. There is no variation in examination style across the current pending workload.
LEITH, NANCY J is the busiest examiner for this portfolio, overseeing 1 busiest examiner pending office action. As this matches the total of 1 pending office action, this examiner is the official currently reviewing the active filings. Practitioners should tailor their arguments to the technical expertise of LEITH, NANCY J in the Biotechnology & Pharmaceuticals sector.
The alignment of 1 distinct art unit with the Biotechnology & Pharmaceuticals area provides the prosecution landscape. With 1 pending office action, the portfolio can be managed with a precise legal strategy. This approach reduces the administrative overhead associated with managing a diverse set of patent applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEITH, NANCY J | 1 | 74.7% | +43.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17368957 | Comprehensive Platform for the DNA and RNA In Human Expression of Dimeric and Polymeric Immunoglobulin A Delivered in a Single Payload | LEITH, NANCY J | 11d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17368957 | Comprehensive Platform for the DNA and RNA In Human Expression of Dimeric and Polymeric Immunoglobulin A Delivered in a Single Payload | LEITH, NANCY J | 11d overdue |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17368957 | Comprehensive Platform for the DNA and RNA In Human Expression of Dimeric and Polymeric Immunoglobulin A Delivered in a Single Payload | LEITH, NANCY J | 1636 | §103§112 | Final Rejection | 11d overdue | Pending | Jul 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRoger B Swartz has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Nancy J Leith has the most, with 1 of Roger B Swartz's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.